Opzelura (ruxolitinib cream) / Incyte, Maruho, China Medical System - LARVOL DELTA

Canadian Consensus Guidelines for the Management of Vitiligo. (PubMed, Dermatol Ther (Heidelb)) - "Improved clarity around the benefits, risks, and limitations of available therapies has supported the development of robust guidelines and a treatment algorithm for vitiligo. Disease stabilization and repigmentation are goals that can largely be achieved, particularly when patients share a mutual understanding of vitiligo and its treatment options. A Graphical Abstract is available for this article."

Journal • Dermatology • Immunology • Vitiligo

Promoting Repigmentation after Epidermal cell suspension grafting and preVENTing the loss of melanocytes using topical ruxolitinib for vitiligo in resistant areas (PREVENT). A prospective monocentric interventional double-blind study. (PubMed, Br J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience. (PubMed, J Dermatol) - "We identified 26 CTCL patients who received a JAKi: 7 received a JAKi prior to their CTCL diagnosis (topical (n = 5) or oral (n = 2) for itchy rash or eczema), 6 received a JAKi as CTCL treatment, and 13 received a JAKi for other indications following a diagnosis of CTCL (oral ruxolitinib for graft versus host disease (GvHD) following allogeneic stem cell transplant (n = 9), oral ruxolitinib for hemophagocytic lymphohistiocytosis (n = 3), or topical ruxolitinib for alopecia areata (n = 1))...This study provides initial insights into the real-world use of JAKi in patients with CTCL. Further studies, however, are required to characterize any association between JAKi use and CTCL development, as well as the safety of JAKi use in the context of pre-existing CTCL."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • Transplantation

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (clinicaltrials.gov) - P2 | N=3 | Not yet recruiting | Sponsor: CAGE Bio Inc.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo (clinicaltrials.gov) - P2 | N=49 | Completed | Sponsor: Incyte Corporation | Active, not recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Mar 2025 | Trial primary completion date: Aug 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • Dermatology • Immunology • Vitiligo

COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=200 ➔ 300

Enrollment change • Dermatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov) - P2 | N=201 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | N=300 ➔ 201 | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment change • Enrollment closed • Dermatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives. (PubMed, Exp Dermatol) - "Noteworthily, despite the exciting results from the oral formulation, no consistent data were described for topical ruxolitinib in alopecia areata. Our review reported encouraging results for many inflammatory skin conditions that should be investigated in further studies."

Journal • Review • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Vitiligo

MORPHEUS: The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (clinicaltrials.gov) - P4 | N=47 | Terminated | Sponsor: Incyte Corporation | N=100 ➔ 47 | Recruiting ➔ Terminated; The study was terminated due to lack of enrollment.

Enrollment change • Trial termination • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Sleep Disorder

GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE STUDY (EBMT 2025) - "The median CD34+ cell count collected was 8.1 × 10⁶/kg.Conditioning regimens included melphalan (63.2%), LEAM (21.1%), BEAM (10.5%), and melphalan with mitoxantrone (5.3%)...Only 1 patient required additional immunosuppressive therapy (cyclosporine and ruxolitinib). Four patients (21.1%) experienced CMV reactivation, which was successfully managed with intravenous ganciclovir.Lenalidomide exposure prior to ASCT was observed in 6 patients (31.6%)... Acute GvHD can occur following ASCT, although its incidence is low (1.5%), and its clinical course is typically milder and more manageable compared to allogeneic transplantation. Conditioning regimen, mobilization protocol, and lenalidomide exposure did not emerge as significant risk factors. Furthermore, aGvHD had no impact on overall survival or recurrence."

Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Multiple Myeloma • Oncology • Transplantation

INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF TOXIC EPIDERMAL NECROLYSIS AND ACUTE GRAFT VERSUS HOST DISEASE OF THE SKIN IN A PEDIATRIC COHORT (EBMT 2025) - "Despite the use of topical steroids, there was progression to 95% BSA and IV methylprednisolone 2 mg/kg/day was started on D+28...Systemic steroids were started on D+46 and ruxolitinib 2.5 mg PO BID was added on D+54... We report three unique cases of grade 4 skin aGVHD with TEN features. Historically, these patients have poor outcomes, however in our experience the addition of IVIG to standard immunosuppression contributed to halting the progression of aGVHD of the skin and resolving the TEN like features. Even though additional immunosuppressive therapies were needed in these patients, we saw resolution of mucosal symptoms, desquamation and eventual improvement of skin rash."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Dermatology • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Sickle Cell Disease • Steven-Johnson Syndrome • T Acute Lymphoblastic Leukemia

Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review. (PubMed, Br J Clin Pharmacol) - "Single-arm trials with baricitinib and abrocitinib provide the highest current evidence for JAK inhibitors in treating genital LS. While evidence for extragenital LS remains limited to case reports, baricitinib shows therapeutic potential. These findings support baricitinib and abrocitinib as potential candidates for future randomized controlled trials."

Journal • Review • Dermatology

Repigmentation of vitiligo with 5-fluorouracil tattooing in combination with topical ruxolitinib: A case report. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Possible ruxolitinib-associated acquired epidermodysplasia verruciformis and skin cancers: a case report (EADO-WCM 2025) - "The patient had a history of nonmelanoma skin cancers (NMSCs) and viral warts, previously treated with cryotherapy, topical imiquimod, and surgeries...Acitretin initiation and HPV vaccination were under consideration but have not yet been implemented, as the patient initially received care outside the authors' institution...Its immunosuppressive effects may predispose patients to HPV-related conditions and skin malignancies. Advances in HPV typing and gene sequencing may further aid in identifying AEV lesions with a higher risk of progression to SCC."

Case report • Clinical • Basal Cell Carcinoma • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Polycythemia Vera • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

EXTRACORPORAL PHOTOPHERESIS (ECP) IN STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): EFFICACY AND SAFETY PROFILE. (EBMT 2025) - "ECP can also be paired with other second line options as ruxolitinib... Our findings suggest that ECP is a safe and effective option in improving cGVHD grade and leading to the interruption or reduction of IS, reducing the side effects of IS without any increase the risk of infections during treatment. However, further data are needed to correlate clinical response to treatment with biological levels of inflammatory markers (ST2, IL2-R, IL-6), but our first findings are promising. Additionally, in patients who achieved an early response, longer treatment duration appears to increase the depth of response."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • IL6

TERRITORY-WIDE RETROSPECTIVE REVIEW ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR HAEMOGLOBIN BART'S HYDROPS FETALIS SYNDROME IN HONG KONG (EBMT 2025) - "Apart from mild grade II acute graft-versus-host-disease (GVHD) of skin which resolved readily with topical steroid/tacrolimus and ruxolitinib, there were no features of severe acute GVHD or chronic GVHD... To conclude, local data demonstrated favorable outcome of allogeneic HSCT for BHFS patients. Non-directive approach in antenatal counseling and international collaboration is recommended. Haploidentical HSCT for BHFS patients using TCRab-depleted graft is a safe and feasible therapeutic option."

Retrospective data • Review • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Transplantation

INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF TOXIC EPIDERMAL NECROLYSIS AND ACUTE GRAFT VERSUS HOST DISEASE OF THE SKIN IN A PEDIATRIC COHORT (EBMT 2025) - "Despite the use of topical steroids, there was progression to 95% BSA and IV methylprednisolone 2 mg/kg/day was started on D+28...Systemic steroids were started on D+46 and ruxolitinib 2.5 mg PO BID was added on D+54... We report three unique cases of grade 4 skin aGVHD with TEN features. Historically, these patients have poor outcomes, however in our experience the addition of IVIG to standard immunosuppression contributed to halting the progression of aGVHD of the skin and resolving the TEN like features. Even though additional immunosuppressive therapies were needed in these patients, we saw resolution of mucosal symptoms, desquamation and eventual improvement of skin rash."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Dermatology • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Sickle Cell Disease • Steven-Johnson Syndrome • T Acute Lymphoblastic Leukemia

GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE STUDY (EBMT 2025) - "The median CD34+ cell count collected was 8.1 × 10⁶/kg.Conditioning regimens included melphalan (63.2%), LEAM (21.1%), BEAM (10.5%), and melphalan with mitoxantrone (5.3%)...Only 1 patient required additional immunosuppressive therapy (cyclosporine and ruxolitinib). Four patients (21.1%) experienced CMV reactivation, which was successfully managed with intravenous ganciclovir.Lenalidomide exposure prior to ASCT was observed in 6 patients (31.6%)... Acute GvHD can occur following ASCT, although its incidence is low (1.5%), and its clinical course is typically milder and more manageable compared to allogeneic transplantation. Conditioning regimen, mobilization protocol, and lenalidomide exposure did not emerge as significant risk factors. Furthermore, aGvHD had no impact on overall survival or recurrence."

Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Multiple Myeloma • Oncology • Transplantation

TERRITORY-WIDE RETROSPECTIVE REVIEW ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR HAEMOGLOBIN BART'S HYDROPS FETALIS SYNDROME IN HONG KONG (EBMT 2025) - "Apart from mild grade II acute graft-versus-host-disease (GVHD) of skin which resolved readily with topical steroid/tacrolimus and ruxolitinib, there were no features of severe acute GVHD or chronic GVHD... To conclude, local data demonstrated favorable outcome of allogeneic HSCT for BHFS patients. Non-directive approach in antenatal counseling and international collaboration is recommended. Haploidentical HSCT for BHFS patients using TCRab-depleted graft is a safe and feasible therapeutic option."

Retrospective data • Review • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Transplantation

Real-World Assessment of Ruxolitinib Cream (AJMC) - "Ruxolitinib cream demonstrated clinical benefits on par with systemic therapies for moderate AD, according to real-world physician-reported outcomes...The study analyzed data from the Adelphi Atopic Dermatitis Disease-Specific Programme (wave 3, August 2022–March 2023). The program included 619 adults with moderate AD: 122 treated with ruxolitinib cream, 80 with systemic immunosuppressants, 264 with oral JAK inhibitors, and 153 with biologics....Patients using ruxolitinib cream saw their affected body surface area (BSA) decrease from 16.5% to 8.5% over an average of 7.4 months, with 48.4% experiencing a reduction in disease severity. The improvements were similar to those observed with oral JAK inhibitors (51.5%) and biologics (46.4%), while only 6.3% of patients on systemic immunosuppressants reported the same benefit."

Real-world evidence • Atopic Dermatitis

Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Adolescent and adult patients with vitiligo who applied ruxolitinib cream could achieve clinically meaningful repigmentation per F-VASI75 response at 1 year, regardless of their baseline demographics or clinical characteristics. Ruxolitinib cream was well tolerated, with a similar incidence of treatment-emergent and treatment-related AEs across subgroups."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Vitiligo

Hot Topics 2024 and 2025 in dermatology (PubMed, Rev Med Suisse) - "Ruxolitinib cream offers new hope for vitiligo, though reimbursement remains uncertain...Concerns about a potential link between dupilumab and cutaneous T-cell lymphoma call for increased clinical vigilance. Meanwhile, bimekizumab marks a breakthrough in hidradenitis suppurativa treatment. Addressing Trichophyton indotineae resistance requires complex strategies. Finally, innovative laser targeting sebaceous glands offers new hope for acne."

Journal • Acne Vulgaris • Cutaneous T-cell Lymphoma • Dermatology • Eosinophilia • Hematological Malignancies • Hidradenitis Suppurativa • Immunology • Lymphoma • Oncology • Psoriasis • Pustular Psoriasis • T Cell Non-Hodgkin Lymphoma • Vitiligo

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Innovaderm Research Inc. | Trial primary completion date: Feb 2025 ➔ Feb 2026 | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. (PubMed, J Dermatolog Treat) - P2 | "Application site reactions were infrequent (ruxolitinib cream, 1.9% [n = 1]; vehicle, 8.7% [n = 2]). Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated."

Clinical • Journal • Monotherapy • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology